Anacor Pharmaceuticals to Present at the UBS Global Health Care Conference

  Anacor Pharmaceuticals to Present at the UBS Global Health Care Conference

UBS 2014 Global Healthcare Conference

Business Wire

PALO ALTO, Calif. -- May 13, 2014

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns,
the company’s President and Chief Executive Officer, will provide a company
overview at the UBS Global Health Care Conference on Monday, May 19, 2014 at
4:00 p.m. ET in New York, New York. The event will be webcast live and may be
accessed under “Events and Presentations” on the Investors page of Anacor’s
website at www.anacor.com. A replay will also be available for three months
following the presentation.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor’s two lead product candidates are topically
administered dermatologic compounds — Kerydin, a topical antifungal in
development for the potential treatment of mild-to-moderate onychomycosis, and
AN2728, an anti-inflammatory PDE-4 inhibitor in development for the potential
treatment of mild-to-moderate atopic dermatitis and psoriasis. In addition to
its two lead product candidates, Anacor has discovered three other
wholly-owned clinical product candidates — AN2718 and AN2898, which are backup
compounds to Kerydin and AN2728, respectively, and AN3365, an antibiotic in
development for the treatment of infections caused by Gram-negative bacteria.
Anacor has also discovered three other compounds that have been out-licensed
for further development — one is licensed to Eli Lilly and Company for the
treatment of an animal health indication, the second compound, AN5568, also
referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases
initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping
sickness) and the third compound is licensed to GlaxoSmithKline, LLC for
tuberculosis. Anacor also has a pipeline of other internally discovered
topical and systemic boron-based compounds in earlier stages of research and
pre-clinical development. For more information, visit http://www.anacor.com.

Contact:

Anacor Pharmaceuticals, Inc.
DeDe Sheel, 650-543-7575
Senior Director, Investor Relations and Corporate Communications
 
Press spacebar to pause and continue. Press esc to stop.